INNV — InnovAge Holding Corp
NASDAQ · Health Care · Health Care
- Latest Close
- $7.65
- 30-Day Move
- +41.7%
- Market Cap
- $1.0B
- Shares Outstanding
- 135,700,000
- P/E Ratio
- 159.51
- P/B Ratio
- 2.13
Analyst consensus: Sell · 9 analysts
InnovAge Holding Corp
A read-only Alphactor snapshot forInnovAge Holding Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-22
Topline snapshot
Latest Close
$7.65
30-Day Move
+41.7%
Market Cap
$1.0B
Shares Outstanding
135,700,000
P/E Ratio
159.51
P/B Ratio
2.13
$7.65
+41.7%last 90 delayed daily bars
90D High
$10.69
90D Low
$5.13
Avg Volume
273,279
Gross margin is running at 20.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 71.0%, useful for comparing INNV against peers in Health Care.
INNV is up 41.7% over the last 30 trading days shown on this page.
Latest operating income is $-16M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$17.07
Rule of 40
14.9%
Latest Close
$7.65
30-Day Move
+41.7%
Market Cap
$1.0B
Shares Outstanding
135,700,000
P/E Ratio
159.51
P/B Ratio
2.13
ROE
-12.9%
ROA
-5.8%
Gross Margin
20.3%
Operating Margin
1.0%
Net Margin
71.0%
Debt / Equity
0.31
Current Ratio
1.07
Latest Revenue
$854M
Revenue
$854M
Gross Profit
$154M
Operating Income
$-16M
Net Income
$-30M
Gross Margin
2034.0%
Net Margin
71.0%
Current Ratio
1.07
Debt / Equity
0.31
Fair Value
$17.07
Upside / Downside
+123.1%
Signal
Undervalued
Implied Growth
16.9%
DCF
$2.96
EV/Rev
$31.18
Growth Assumption
6.9%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$27M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
3.62
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
-1.08x
Rule of 40
14.9%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $699M | $-4M | $-7M | $-11M |
| 2023-12-31 | $688M | $-49M | $-41M | $-3M |
| 2024-12-31 | $764M | $-23M | $-21M | $-45M |
| 2025-12-31 | $854M | $-16M | $-30M | $27M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
BlackRock
Filed 2024-08-13
$6M
--
Vanguard Group
Filed 2026-01-29
$6M
+1.4%
Geode Capital Management
Filed 2026-02-09
$3M
-0.1%
Marshall Wace
Filed 2026-02-13
$2M
--
Northern Trust
Filed 2025-11-14
$1M
-3.2%
2.33
Consensus
Sell—
—
—
9
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.